China Botanic Pharmaceutical Inc. reported unaudited consolidated earnings results for the first quarter ended January 31, 2012. For the quarter, the company reported net income of $12,307,232 or $0.33 per basic and diluted share on net sales of $28,140,091 against net income of $10,948,295 or $0.29 per basic and diluted share on net sales of $22,625,060 a year ago. Income from operations was $14,450,650 compared to $11,671,727 a year ago. Income before income tax expenses was $14,482,757 compared to $11,671,727 a year ago. Net cash provided by operating activities was $3,358,465 compared to $1,300,790 a year ago. The significant revenue growth was mainly due to price increases across all of the company's products during the quarter and the increasing market recognition of the company's Siberian Ginseng Series products and other new products, such as Ginseng and Venison Extract and Badger Oil as a result of China Botanic's marketing efforts. For fiscal year 2012, the company reaffirmed its guidance of revenues of between $91.6 million and $93.1 million, representing an increase of 26% to 28% over fiscal year 2011 revenue of $72.7 million. Revenue growth is expected to be driven largely by sales volume increases from the existing product portfolio. The company expects net income to be in the range of $32.7 million to $33.2 million, representing an increase of between 26% and 28% over fiscal year 2011 net income of $25.9 million.